[go: up one dir, main page]

WO2002040071A1 - Compositions stimulant la formation d'un os ou d'un parodonte et injections pour la formation d'un os ou d'un parodonte - Google Patents

Compositions stimulant la formation d'un os ou d'un parodonte et injections pour la formation d'un os ou d'un parodonte Download PDF

Info

Publication number
WO2002040071A1
WO2002040071A1 PCT/JP2001/009800 JP0109800W WO0240071A1 WO 2002040071 A1 WO2002040071 A1 WO 2002040071A1 JP 0109800 W JP0109800 W JP 0109800W WO 0240071 A1 WO0240071 A1 WO 0240071A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone
composition
cells
prp
periodontal tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/009800
Other languages
English (en)
Japanese (ja)
Inventor
Minoru Ueda
Yasuhiro Okazaki
Ken-Ichiro Hata
Youichi Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSTEOGENESIS CO Ltd
Original Assignee
OSTEOGENESIS CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSTEOGENESIS CO Ltd filed Critical OSTEOGENESIS CO Ltd
Priority to AU2002212739A priority Critical patent/AU2002212739A1/en
Priority to JP2002542441A priority patent/JPWO2002040071A1/ja
Publication of WO2002040071A1 publication Critical patent/WO2002040071A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3616—Blood, e.g. platelet-rich plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Definitions

  • the present invention relates to a composition for forming bone or periodontal tissue that can be used for repairing or regenerating bone or periodontal tissue.
  • PRP Platelet-rich Plasma
  • Fiblin Glue fibrin glue
  • PRP Planar-derived Growth Factor
  • TGF- ⁇ 1 Transforming growth factor ⁇ 1
  • TGF- Transforming growth factor ⁇ 2
  • PDGF is a glycoprotein having a molecular weight of about 30 kD and has been confirmed to have an effect of promoting wound healing.
  • PDGF promotes cell mitosis, improves blood circulation by promoting the formation of capillaries, or promotes differentiation and proliferation of fibroblasts, osteoblasts, etc. by enhancing the effects of other growth factors. Is thought to promote wound healing.
  • the present invention aims at providing a composition for forming bone or periodontal tissue used in the method in order to provide a novel method for regenerating bone or periodontal tissue which can be applied to clinical practice.
  • Target a composition for forming bone or periodontal tissue used in the method in order to provide a novel method for regenerating bone or periodontal tissue which can be applied to clinical practice.
  • the present inventors have conducted intensive studies in view of the above problems. First, when a transplant material was constructed by combining PRP and an inorganic bioabsorbable material, and bone regeneration was examined using this material, the bone inducing ability for cells existing in the adaptation site at the application site was amplified. And a high bone regeneration effect was found. It was also suggested that inclusion of a particulate inorganic bioabsorbable material in PRP facilitates appropriate plasticity and shape retention.
  • a first aspect of the present invention is a composition for forming a bone or periodontal tissue, which comprises PRP and an inorganic bioabsorbable material and has fluidity during use.
  • a second aspect of the present invention is a composition for forming a bone or periodontal tissue having fluidity at the time of use, comprising PRP and cells having an osteogenic ability.
  • Still another aspect of the present invention is a composition for forming a bone or periodontal tissue having fluidity during use, comprising fibrinogen, an inorganic bioabsorbable material, and cells having bone forming ability. It is. Still another aspect of the present invention is a composition for forming bone or periodontal tissue having fluidity during use, comprising PRP, alginate (alginate), and cells having bone forming ability. It is.
  • the fluidity of the composition for forming bone or periodontal tissue depends on the injection container at the time of use. It is preferable to have fluidity that can be used by injection.
  • composition for forming bone or periodontal tissue of the present invention can be prepared further containing a gelling material.
  • Thrombin and calcium chloride can be used as the gelling material.
  • composition for forming bone or periodontal tissue of the present invention can be used after being frozen once and then thawed from the frozen state at the time of use.
  • composition for forming bone or periodontal tissue can be sealed in an injection container to form an injection for forming bone or periodontal tissue.
  • the inorganic bioabsorbable material in the present invention includes one selected from the group consisting of: 3-tricalcium phosphate, ⁇ -tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, and amorphous calcium phosphate.
  • two or more inorganic bioabsorbable materials can be used.
  • the inorganic bioabsorbable material those having an average particle diameter of 0.5 m to 50 / m can be used.
  • the content of the inorganic bioabsorbable material can be, for example, 30% by weight to 75% by weight.
  • the growth site can be used at an application site (transplant site) by these growth factors. Effective regeneration of bone tissue or periodontal tissue can be expected.
  • it since it has fluidity at the time of use, it is versatile because it is not necessary to pre-mold it in accordance with the shape of the bone or periodontal tissue defect, and its handling is easy.
  • autologous PRPs allows the application of non-toxic and immune-inactive growth factors, and their safety is high.
  • the inorganic bioabsorbable material becomes a scaffold for bone cells and the like at the application site, and can further promote regeneration of bone tissue and the like.
  • inorganic bioabsorbable materials will be replaced by bone tissue in the future. Its safety is high.
  • a bone or periodontal tissue defect can be effectively repaired and regenerated without collecting autologous bone, and bone or bone having high operability and safety can be obtained.
  • a composition for periodontal tissue formation is provided.
  • Fig. 1 shows a photograph of the results of the PRP group in Example 4 (right side of the maxillary sinus implanted with the PRP gel containing / 3-TCP) two weeks after transplantation.
  • Gray HE Hematoxylin Eosin stained histology is shown.
  • 3-TCP accumulates and fills the transplanted bone, and a large number of osteoblasts surround it. Osteoblasts are also observed in 13-TCP. Juvenile new bone is observed around some
  • FIG. 2 is a photograph showing the results of the 4 weeks after transplantation of the PRP group (the right side of the maxillary sinus transplanted with the PRP gel containing / 3-TCP) in Example 4; Gray HE (Hematoxylin Eosin) stained histology is shown. I3-TCP has decreased compared to 2 weeks after transplantation. ) It is observed that osteoblasts are encapsulated all around the 3-TCP. In addition, the formation of new bone is observed around 3-TCP. It is observed that many osteoblasts also exist around the new bone. There is a cement line in the new bone.
  • FIG. 3 is a photograph showing the results of the control group in Example 4 (left side of the maxillary sinus to which only I3-TCP was transplanted) two weeks after transplantation. Hematoxylin eosin) The stained histology is shown. ) 3-TCP is present in the transplanted bone as a square, and osteoblasts are observed around J3-TCP. Also, Slight formation of new bone is observed.
  • FIG. 4 is a photograph showing the results of the control group in Example 4 (left side of the maxillary sinus transplanted with only
  • Fig. 5 is a photograph showing the results of the PRP group in Example 4 (the right side of the maxillary sinus transplanted with the PRP gel containing / 3-TCP) 8 weeks after transplantation, and demineralization of the transplanted portion 8 weeks after transplantation.
  • HE hematoxylin eosin stained histology is shown. Increased bone mass is seen at and around the implant.
  • Figure 6 is an enlarged (16x) view of a portion of Figure 5.
  • the formation of new bone (B) is observed so as to be in contact with the i3-TCP-containing PRP gel implant (A).
  • FIG. 7 is an enlarged (16x) view of a part of Fig. 5, similar to Fig. 6.
  • formation of new bone (B) is observed so as to be in contact with the 3-TCP-containing PRP graft (A).
  • FIG. 8 is a photograph showing the results of the control group in Example 4 (left side of the maxillary sinus transplanted with -TCP alone) at 8 weeks after transplantation. (Matoxylinje) A stained histological image is shown. There is almost no increase in bone mass compared to 4 weeks after transplantation.
  • Figure 9 is an enlarged (16x) view of part of Figure 8. It is observed that the fibrous connective tissue (c) surrounds the j3-TCP gel implant (a). Bone (b) is outside fibrous connective tissue (c).
  • FIG. 10 is a graph summarizing the results of Example 4, and shows the ratio (%) of the ossified portion to the entire transplanted portion. The amounts of newly formed bone and the amount of 3-TCP remaining at 2, 4 and 8 weeks after transplantation are shown.
  • (+) indicates the results of the PRP group
  • (1) indicates the results of the control group. 8 weeks after transplantation It can be seen that the amount of new bone in the test group is significantly higher than that in the control group. It is also observed that the PRP group absorbed 0-TCP better.
  • FIG. 11 is a photograph showing two weeks (2 W), four weeks (4 W), and eight weeks (8 W) after transplantation of the PCBM transplanted part in Example 8, and demineralization of the transplanted part.
  • HE hematoxylin eosin stained histology is shown.
  • FIG. 12 is a diagram showing photographs at two weeks (2 W), four weeks (4 W), and eight weeks (8 W) after the transplantation of the PRP-cell gel-transplanted part in Example 8.
  • the decalcified HE (hematoxylin eosin) stained histology is shown.
  • FIG. 13 is a diagram showing photographs of the results at 2 weeks (2 W), 4 weeks (4 W), and .8 weeks (8 W) after the transplantation of the PRP gel transplant portion in Example 8.
  • the decalcified HE (hematoxylin eosin) stained histology is shown.
  • FIG. 14 is a view showing a photograph of the result of the control group in Example 8. Photographs at 2 weeks (2 W), 4 weeks (4 W), and 8 weeks (8 W) of the defect left untransplanted, with decalcified HE (hematoxylin and eosin) staining The histology is shown.
  • FIG. 15 is a photograph showing a directly observed transplantation site 8 weeks after the transplantation of the transplantation composition (fibrinogen-j3-TCP-cell-containing composition). A white lump is observed at the transplant (arrow).
  • Fig. 16 shows the HE-stained tissue images at 2 weeks (2W), 4 weeks (4W), and 8 weeks (8W) after transplantation of the transplantation composition (fibrinogen-) 3-TCP-cell-containing composition.
  • 8 weeks (8W) after transplantation a partial laminar structure is seen (arrow), and bone maturation can be observed.
  • FIG. 17 is a view showing an HE-stained tissue image of the control group with the transplantation composition (fibrinogen-
  • FIG. 18 (A) is a diagram showing an H.E.-stained tissue image of the transplanted part 16 weeks after transplantation of (PRP-alginate-one-cell-containing composition).
  • FIG. 18 (B) is a view showing an H.E.-stained tissue image of the transplanted portion 16 weeks after transplantation of the control group (transplanted with alginate).
  • the group (A) into which the composition for transplantation was transplanted new bone was observed (arrow), and it was confirmed that bone regeneration was performed.
  • the transplanted alginate is observed by staining (arrow), but no new bone formation is observed.
  • PRP refers to platelet-rich plasma, that is, a platelet-rich plasma. In other words, it refers to platelet-enriched plasma.
  • PRP is prepared, for example, by subjecting collected blood to centrifugation according to the method of Whitman et al. (Dean H. Whitman et al .: J Oral Maxillofac Surg, 55, 1294-1299 (1997)). can do.
  • PRP is known to be rich in growth factors such as Platelet-derived Growth Factor (PDGF), Transforming growth factor ⁇ 1 (TGF- ⁇ 1), and Transforming growth factor ⁇ 2 (TGF- ⁇ 2).
  • PDGF Platelet-derived Growth Factor
  • TGF- ⁇ 1 Transforming growth factor ⁇ 1
  • TGF- ⁇ 2 Transforming growth factor ⁇ 2
  • darry J. Peterson Oral surg Oral Med Oral Pathol Oral Radiol Endod, 85, 638-646 (1998)).
  • an example of a method for preparing PRP is as follows. First, an anticoagulant such as sodium citrate is added to the collected blood and left at room temperature for a predetermined time. Thereafter, centrifugation is performed under conditions (for example, about 5,400 rpm) at which blood cells and buffy coat separate. This separates into two layers (the upper layer is called platelet-poor plasma; the lower layer contains blood cells and buffy coat). After removing the upper layer, centrifugation is further performed under conditions that allow red blood cells to be separated (for example, about 2,400 rpm). The resulting fraction substantially free of red blood cells (Platelet-rich Plasma: PRP) is collected. How to prepare PRP The method is not limited to this method, and can be prepared by a method modified as necessary.
  • an anticoagulant such as sodium citrate is added to the collected blood and left at room temperature for a predetermined time. Thereafter, centrifugation is performed under conditions (for example, about 5,400 rpm) at which blood cells and buffy coat separate. This separate
  • autologous PRP is used. This eliminates the risk of toxicity or immune rejection.
  • PRP is rich in platelet, growth factors such as TGF-i31, TGF- ⁇ 2, and fibrinogen. Therefore, platelets, a growth factor such as TGF-i31, and fibrinogen can be prepared, and a mixture thereof can be used as the PRP in the present invention. Platelets, various growth factors, and fibrinogen can be prepared by a known method or commercially available. On the other hand, PRP is particularly rich in platelets and has a high fibrinogen content.Therefore, instead of PRP, platelets, fibrinogen, or platelets and fibrinogen are used to form bone or periodontal tissue. It is expected that a bone regenerating effect can be obtained even when the composition for use is constituted.
  • the bone or periodontal tissue forming composition of the present invention by using platelets, fibrinogen, or platelets and fiprinogen instead of PRP.
  • fibrin can be used instead of fibrinogen here. That is, for example, the composition of the present invention can be constituted by containing fibrin glue instead of PRP.
  • the degree of fluidity during use of the composition of the present invention is not particularly limited, and may be a gel, a slurry, a paste, a clay, a high-viscosity fluid, or the like. Preferably, it is in the form of a gel or a paste. Possible by gel or paste A composition for forming bone or periodontal tissue having excellent plasticity is obtained. Therefore, it can be applied without being previously formed into the shape of the application portion. That is, application to the application section can be easily performed. In addition, a composition for forming a bone or a periodontal tissue having a good fixation property in an application portion is obtained.
  • the fluidity is such that it can be injected using an injection container at the time of use. With such fluidity, application to the application section becomes even easier.
  • desired fluidity can be obtained depending on the application section. For example, when injecting under the periosteum, it is preferable to make the liquid more fluid (a state having a lower viscosity).
  • the composition of the present invention only needs to have fluidity at least at the time of use, and may be in the form of powder or solid before use. Therefore, the composition of the present invention can be in a frozen state. Further, the composition of the present invention can be used in a lyophilized state. By making the frozen or lyophilized state before use, long-term storage becomes possible, and handling before use becomes easy. Furthermore, since the antigenicity can be expected to be reduced by the freeze treatment or the freeze-drying treatment, the safety when using the same kind of PRP instead of the own PRP is improved.
  • the kind of the inorganic bioabsorbable material in the present invention is not particularly limited, tricalcium phosphate (hereinafter, referred to as “—TCPJ”), ⁇ -tricalcium phosphate (hereinafter, referred to as “ ⁇ -TCPJ”), tetracalcium phosphate
  • TCPJ tricalcium phosphate
  • ⁇ -TCPJ ⁇ -tricalcium phosphate
  • tetracalcium phosphate A material selected from the group consisting of octacalcium phosphate, and amorphous calcium phosphate can be used, and these materials can be used alone, or a combination of two or more arbitrarily selected materials can be used.
  • i3-TC ⁇ or ⁇ -TC ⁇ , or a combination of these in any proportion is used.
  • 3-TCP is used as the inorganic bioabsorbable material. .
  • the inorganic bioabsorbable material can be obtained by a known method.
  • commercially available inorganic bioabsorbable materials can also be used.
  • jS—For TCP for example, Olympus Optical Industrial Co., Ltd. can be used.
  • the inorganic bioabsorbable material is in the form of powder having a particle size such that the composition for forming bone or periodontal tissue of the present invention (hereinafter, referred to as “the present invention composition”) becomes fluid when used. Is preferred.
  • the powdered inorganic bioabsorbable material can be prepared by crushing and pulverizing an inorganic bioabsorbable material processed into an appropriate size to a desired particle size.
  • the average particle size of the inorganic bioabsorbable material is 0.5! It is preferably set to 50 / m. More preferably, an inorganic bioabsorbable material having an average particle diameter of 0.5; tim to 10 / m is used. Still more preferably, the average particle diameter is 1 t ⁇ ! Use an inorganic bioabsorbable material of ⁇ 5 // m. It is also possible to use a combination of a plurality of types of inorganic bioabsorbable materials having different particle diameters.
  • the inorganic bioabsorbable material preferably contains 30% by weight to 75% by weight based on the whole composition of the present invention.
  • the fluidity of the composition of the present invention can be adjusted by the particle size and content of the inorganic bioabsorbable material, and a desired fluidity can be obtained by appropriately adjusting both.
  • a gelling material and / or a thickener described below are added, the fluidity can be adjusted also by the amount of these added.
  • the composition of the present invention may further comprise a gelling material.
  • the composition of the present invention can be constituted by adding thrombin and calcium chloride. By adding them, thrombin acts on fibrinogen in PRP to generate fibrin. Then, the viscosity increases due to the aggregation action of fibrin.
  • the type of the gelling agent is not particularly limited, and those which act on the components in the PRP to increase the viscosity as described above or those which exert a thickening effect by themselves can be appropriately selected and used.
  • composition of the present invention acts after application (after transplantation) 9800
  • a second gelling material that changes the fluidity (viscosity) of No. 12 can also be used in combination.
  • transplantation is easy because of appropriate fluidity at the time of use, and fixation at the application site is improved by increasing the viscosity after application, and bone or periodontal tissue Repair or regeneration can be performed effectively.
  • fixation at the application site is improved by increasing the viscosity after application, and bone or periodontal tissue Repair or regeneration can be performed effectively.
  • the gelling material a material having high biocompatibility is preferably used.
  • collagen or fipurin glue can be used.
  • various collagens can be selected and used, it is preferable to use collagen suitable for the application purpose (application tissue) of the composition of the present invention.
  • application tissue for example, type I collagen can be used.
  • the collagen used is preferably soluble (acid-soluble collagen, alkali-soluble collagen, enzyme-soluble collagen, etc.).
  • the flowability of the composition of the present invention can be adjusted by adding a thickener.
  • a thickening agent thickening polysaccharides such as sodium alginate, glycerin, petrolatum, etc. can be used.However, from the viewpoint of safety and Z or bone formation ability, it has high biocompatibility and is bioabsorbable or bioabsorbable. It is preferable to use a decomposable material. By adding glycerin and the like, the effect of preventing frost damage can be obtained.
  • alginate alginate
  • PRP PRP
  • the composition of the present invention may contain an aqueous solvent. That is, in the first aspect of the present invention, at least PRP and an inorganic bioabsorbable material may be mixed in an aqueous solvent. In the second aspect of the present invention, at least PRP and cells having osteogenic ability are mixed in an aqueous solvent. It may be configured.
  • aqueous solvent sterile water, physiological saline, a buffer solution such as a phosphate solution and the like can be used.
  • composition of the present invention may contain, in addition to the above components, a stabilizer, a preservative, a pH adjuster, and the like. It can also contain growth factors, especially osteoinductive factors (BMP).
  • BMP osteoinductive factors
  • the cells having osteogenic ability refer to cells capable of forming bone tissue, and include osteoblasts, preosteoblasts, mesenchymal stem cells that have acquired the ability to differentiate into osteogenic cells, and the like. These cells may be used in any combination.
  • J that has acquired the ability to differentiate into bone cells refers to a state in which an undifferentiated state has been oriented to differentiate into bone cells.
  • mesenchymal stem cells that have acquired the ability to differentiate into bone cells
  • autologous cells not only autologous cells but also allogeneic allogeneic cells
  • allogeneic allogeneic cells can be used.
  • cells derived from human mesenchymal stem cells can be used.
  • osteoblast-acquiring cells convert undifferentiated mesenchymal stem cells (MSCs) into bone cells.
  • MSCs mesenchymal stem cells
  • the culture conditions are not limited to those described above, and known conditions for inducing differentiation into bone cells can be employed.
  • Sources of undifferentiated mesenchymal stem cells include bone marrow, periosteum, pulp, and cord blood. After collecting them according to a conventional method, undifferentiated mesenchymal cells are selected based on the presence or absence of adhesiveness. In other words, select cells that have adhesive properties from cells contained in bone marrow, etc. As a result, undifferentiated mesenchymal stem cells can be obtained.
  • the present invention composition can be constituted by adding the extracellular matrix of the cells.
  • the extracellular matrix is expected to serve as a scaffold for the cells having the ability to acquire bone differentiation at the site to which the composition of the present invention is applied, and it is considered that the cells having the ability to acquire bone differentiation can be easily fixed at the site to which the composition is applied.
  • it also serves as a scaffold for bone cells existing around the application site, so that high bone inducing ability can be expected.
  • BMPs and other factors contained in the extracellular matrix are included in the composition of the present invention, and the cells having the ability to differentiate into osteogenic cells themselves, and the bone cells around the application site or stem cells having the ability to differentiate into osteogenic cells. It is expected to promote growth, proliferation and differentiation.
  • the extracellular matrix is a matrix (matrix) that surrounds the cells having the osteogenic potential.
  • the extracellular matrix of autologous cells but also the extracellular matrix of allogeneic cells of the same type can be used. This is because BMPs and the like contained in such extracellular matrix are of the same species, so that the same effect can be expected even when allogeneic cells are used. As described above, the fact that not only the extracellular matrix of autologous cells but also the extracellular matrix of allogeneic cells can be used facilitates the preparation of the extracellular matrix of cells having the osteogenic differentiation potential.
  • the cells with the ability to acquire bone differentiation potential added simultaneously may not be living cells. This means that it is not necessary to treat the cells with the ability to acquire bone differentiation potential in the state of living cells, which is desirable from the viewpoint of handling. For example, after obtaining cells having bone differentiation potential, those obtained by freeze-drying or the like are prepared, and these can be used as cells having bone differentiation potential and their extracellular matrix.
  • the content of the bone based differentiation capacitation cells in the compositions of the present invention is preferably be 1 X 1 0 5 or more cells are present in lml, more preferably 1 X 1 0 6 ⁇ 1 X 1 it is preferable that 0 7 cells are present. This is because by setting such a cell content, bone formation can be effectively induced.
  • a composition for forming bone or periodontal tissue can be constituted by containing the above-mentioned cells having bone forming ability. In this case, the composition may be constituted by adding the extracellular matrix (extracellular matrix) of the cells having the ability to obtain bone differentiation.
  • the composition of the present invention is prepared by mixing the above components.
  • a method for preparing a gel composition by mixing PRP,) 3-TCP (inorganic bioabsorbable material), and thrombin and calcium chloride An example is shown below.
  • PRP is prepared by the method described above, and / 3-TCP is added thereto and mixed. Then, add a mixture of calcium chloride solution and thrombin, and stir well with air in the syringe.
  • the composition of the present invention When the composition of the present invention is prepared in a frozen state or a lyophilized state, the composition has a desired fluidity when used. In the case of a frozen state, it is returned to the state before freezing by thawing. At this time, a desired fluidity can be adjusted by adding physiological saline or the like. On the other hand, in the case of a freeze-dried state, a solvent such as physiological saline is added to obtain a fluidity before the freeze-drying treatment or a state having a desired fluidity.
  • an injection for bone or periodontal tissue formation (hereinafter referred to as “the injection of the present application”) can be obtained.
  • the composition of the present invention prepared in a fluid state is sealed in an injection container, and then frozen or freeze-dried to obtain the injection of the present invention.
  • handling becomes easier. That is, a desired effect can be expected by injecting the present injection transdermally or transmucosally without making an incision in the skin or mucous membrane as in the prior art at the time of application.
  • Such an injection of the present invention is used after the bone or periodontal tissue forming composition enclosed therein is brought into a state having desired fluidity similarly to the above.
  • the type of injection container is not particularly limited, and for example, a commercially available syringe can be used.
  • Each preserved blood sample was transferred to a 10 ml centrifuge tube, and centrifuged at 5,400 rpm for 5 minutes using a centrifuge.
  • the centrifuged blood separated into three layers depending on the density. In order from the upper layer, there are three layers: Platelet-poor Plasma (Platelet-free plasma, PPP), Platelet-rich Prasma (PRP), and red blood cells.
  • PPP Platelet-poor Plasma
  • PRP Platelet-rich Prasma
  • red blood cells The top PPP (approximately 5.5 ml) was removed using a micro-mouth pipet.
  • the remaining blood components about 3.5 ml
  • red blood cells and PRP were separated.
  • the upper layer was PRP, which was collected using a micropit. About 0.35 ml of PRP was finally collected from each blood sample (9 ml).
  • 3-TCP powder was placed in a 2.5 ml syringe (manufactured by Terumo Corporation). 35 ml of the PRPO prepared in Example 1 was aspirated with a micropipette; injected into a syringe containing 8-TCP powder; and mixed with) 3-TCP powder. After stirring well in a syringe, j8-TCP was dissolved in PRP. On the other hand, a mixture of 10 ml of 10% calcium chloride solution and 10,000 units of bovine thrombin (GEN-TRAC) for topical use was prepared, and 0.035 ml of this mixture was added to a syringe containing 3-TCP and PRP. Mix with O.lcc air in syringe. This initiated coagulation and formed a / 3-TCP containing PRP gel.
  • GRP bovine thrombin
  • Example 2 Twenty-four (24) Japanese white egrets from which blood was collected in Example 1 were shaved. After shaving, the remaining hair in the shaved area was completely removed with a depilatory cream. Next, the heron was fixed on the stomach, and the surgical field was disinfected with a chlorhexidine dalconate swab. After that, a 10 mm length skin incision was made in the upper part, and the mucosa and periosteum were peeled off to expose the bone surface of the anterior wall of the maxillary sinus. Then, the bone of the anterior wall of the maxillary sinus was removed with a diameter of about 7 mm using a dental diamond blade. Finally, the maxillary sinus mucosa was carefully dissected upward using an exfoliator to form a space for transplantation of the PRP gel containing / 3-TCP. (4-1-2)) 3—Transplantation of TCP-containing PRP grey
  • Example 3 Obtained in Example 3; 0.175 ml of PRP gel containing 8-TCP was weighed and collected by using a 5 mm ⁇ 5 mm ⁇ 7 mm homemade space maker and implanted into the space of the right maxillary sinus just created. On the left side, a saline solution was used to give the same viscosity as i3-TCP containing PRP gel.) 3-TCP paste was transplanted. After the mucosa and periosteum were returned to their original positions, the wound was closed with suture, and the transplantation of the 3-TCP-containing PRP gel was completed.
  • the bone formation was evaluated by visually observing the transplanted part after a predetermined period. First, at 2 weeks and 4 weeks after transplantation, the heron transplanted at (4-2) was sacrificed, and the upper jaw and nose were removed in one lump. The extract was fixed with a 10% phosphate buffered formalin solution and decalcified with a 10% formic acid aqueous solution. Thereafter, paraffin embedding was performed, a frontal section having a thickness of 5 mm was prepared, stained with hematoxylin eosin, and observed under an optical microscope.
  • Figure 1 shows the transplantation site two weeks after transplantation. J3-TCP was accumulated and filled in the transplanted bone, and a large number of osteoblasts were observed to surround it. Osteoblasts were also observed in the accumulated / 3-TCP. A small amount of new bone was found around some ⁇ -TCP. Platelets were observed throughout the implanted bone. Thus, it was observed that bone formation was progressing as compared with the control group.
  • FIG. 2 shows the state of the transplantation site four weeks after transplantation. 3) TCP decreased compared to 2 weeks after transplantation. It was observed that osteoblasts were encapsulated all around J3-TCP. In addition, new bone formation was observed around J3-TCP, and 2 weeks after transplantation Than had increased. Many osteoblasts also existed around the new bone. In addition, a cement line was found in the new bone. Thus, remarkable bone formation was observed as compared with the control group.
  • Control group left maxillary sinus transplanted with i3-TCP only
  • Figure 3 shows the state of the transplantation site two weeks after transplantation. i3-TCP was present in the transplanted bone as a square, and) osteoblasts were observed around 3-TCP. In addition, new bone formation was slightly observed.
  • Figure 4 shows the transplantation site four weeks after transplantation. Many -TCPs were still observed in blocks at the implant, and new bone formation was observed around them. A cement line was found in the trabeculae of the new bone.
  • FIG. 5 shows the state of the 3-RP containing PRP gel transplantation site (8 weeks after transplantation).
  • Figure 5 shows a hematoxylin-eosin stained image (decalcified H.E. stained tissue image). Increased bone mass is noted at and around the implant.
  • FIG. 6 and 7 show enlarged (16x) parts of Fig. 5. 3)
  • the formation of new bone (B) is observed so as to be in contact with the 3-TCP-containing PRP transplant (A). That is, formation of new bone is observed in a state where no fibrous connective tissue is interposed between the transplanted portion and the new bone.
  • i3-TCP containing PRP gel It has been shown that the transplantation of osteoporosis actively forms new bone, ie, osteoinduction.
  • Control group left maxillary sinus transplanted with i3-TCP only
  • Figure 8 shows the state of the / 3 -TCP gel transplantation site 8 weeks after transplantation.
  • Figure 8 shows the hematoxylin-eosin stained image (decalcified H.E. stained tissue image). There is almost no increase in bone mass compared to 4 weeks after transplantation.
  • Figure 9 shows an enlarged (16x) view of a portion of Figure 8.
  • the fibrous connective tissue (c) surrounds the 3-TCP gel implant (a). That is, fibrous connective tissue (c) is interposed between the transplanted part (a) and the bone (b). Therefore, it is considered that the bone observed in this photograph is not the new bone formed by the induction of (3-graft) induced by 3-TCP, but the bone metabolism originally formed by the living body.
  • FIG. 10 is a graph summarizing the ratio (%) of the ossified portion to the whole transplanted portion. The amount of newly formed bone and the amount of newly formed bone at 2, 4 and 8 weeks after transplantation are shown. -Shows the remaining amount of TCP. In the figure, (+) indicates the results for the PRP group, and (-) indicates the results for the control group. At 8 weeks after transplantation, the amount of new bone in the PRP group was significantly higher than that in the control group. It can also be seen that the PRP group absorbed) 3-TCP better.
  • Example 2 Before transplantation, blood was collected from two dogs weighing 15-17 kg, and treated in the same manner as in Example 1. PRP was separated and purified. Each blood sample (50 ml) resulted in approximately 5 ml of PRP each. The number of platelets in the PRP was counted in the same manner as in Example 2, and it was confirmed that the platelets were contained abundantly.
  • the iliac bone marrow fluid was collected from a dog iliac bone using a bone marrow puncture needle into a lOcc syringe (manufactured by Terumo Corporation) and injected into a centrifuge tube containing a heparin-containing basic medium.
  • the flask seeded with bone marrow fluid transferred into Inkyubeta were cultured under conditions of 5% C0 2, 37 ° C .
  • the medium was replaced 24 hours after seeding the bone marrow cells in order to remove the blood cells contained in the culture medium and select and adherent cells for culture. Thereafter, culturing was continued for about 7 days in the culture medium until the cells became subconfluent. During that time, medium exchange was performed once every three days.
  • the flask seeded with bone marrow fluid was transferred into Inkyube Isseki were cultured under conditions of 5% C0 2, 37.
  • the medium was replaced 24 hours after seeding the bone marrow cells in order to remove the blood cells contained in the culture medium and select and adherent cells for culture. Thereafter, culturing was continued for about 7 days until the cells became subconfluent in the culture solution. During that time, the medium was changed once every three days.
  • MSCGM, 50 U / ml penicillin G, and 50 pg / ml streptomycin manufactured by Poietics
  • the medium was removed from the flask, leaving a small amount of medium.
  • the cells were detached from the flask using Trypsin / EDTA.
  • the detached cells were transferred to a centrifuge tube (FALCON ECTON DICKINSON USA) together with the medium, and subjected to centrifugation (1500 rpm, 5 min). The supernatant was aspirated and the cell components were collected.
  • Example 6 The cell component recovered in Example 6 was suspended in a small amount of PRP to prepare a cell suspension. 3.5 ml of the PRP obtained in Example 5, 0.5 ml of a 10% calcium chloride solution, and topical bovine thrombin (0000 units of GEN-TRAC) were mixed in a syringe to form a PRP-cell-containing gel.
  • a gel prepared by mixing PRP, a 10% calcium chloride solution, and topical bovine thrombin was prepared as a control.
  • Example 5 The dog from which blood was collected in Example 5 was fixed on the stomach, and the surgical field was disinfected with a chlorhexidine dalconate swab. Then, extract the teeth one month beforehand A skin incision about 100 mm in length was made in the jaw, and the mucosa and periosteum were peeled off to expose the bone surface of the jawbone. Then, using a trephine pad, a jaw bone defect was created with a size of about 10 mm.
  • the bone regeneration ability of each group was histologically evaluated and compared by visually observing the transplanted part after a predetermined period.
  • transplanted parts were removed from dogs transplanted at (8-2).
  • the extract was fixed with a 10% phosphate buffered formalin solution and decalcified with a 10% aqueous formic acid solution. Thereafter, tissue-stained sections were prepared by embedding in paraffin, stained with hematoxylin and eosin, and observed under an optical microscope.
  • PCBM group autologous bone transplantation
  • Figure 11 shows the two weeks (2 W), four weeks (4 W), and eight weeks (8 W) after transplantation of the PCBM transplant. Two weeks after transplantation, it is observed that bone regeneration has already taken place. At the same time, absorption of the transplanted PCBM is also observed. Eight weeks after transplantation, good bone regeneration was obtained up to the margin of the defect (arrow E in the figure).
  • Fig. 12 shows the results of two weeks (2 W), four weeks (4 W), and eight weeks (8 W) after transplantation of the PRP-cell-containing gel transplant. It was observed that the amount of new bone (arrow F in the figure) increased over time after transplantation, and good bone regeneration was performed up to the margin of the defect (arrow G in the figure) at 8 weeks after transplantation. You can see it is being done. It is also observed that precise bone regeneration is being performed. Furthermore, abundant angiogenesis (arrow H in the figure) was observed, It can be seen that the formation of new bone is induced. The degree of bone regeneration at 4 weeks and 8 weeks after transplantation was similar to that of the PCBM group (Fig. 11).
  • Fig. 13 shows the state of the PRP gel transplantation site at 2 weeks (2 W), 4 weeks (4 W), and 8 weeks (8 W) after transplantation. After transplantation, bone regeneration is observed to occur gradually from the bottom of the defect (arrow I in the figure), but the degree of bone regeneration is low. Even at 8 weeks after transplantation, bone regeneration was not performed up to the defect margin (arrow J in the figure).
  • Fig. 14 shows the state of the defect left without transplantation at 2 weeks (2 W), 4 weeks (4 W), and 8 weeks (8 W).
  • the PRP gel group it is observed that osteogenesis occurs gradually from the bottom of the defect (arrow K in the figure).
  • the degree of bone regeneration is extremely low. Even after 8 weeks, almost no bone regeneration has occurred at the periphery of the defect, and fibrous cells are observed to be aggregated (arrow L in the figure).
  • the completed porous 3-TCP block has a three-dimensional porous structure in which all pores are continuous. It was made. Using this, a cylindrical block with a diameter of about 5 mm and a height of about 4 mm was manufactured, and the pore diameter was adjusted to 200 to 400 ⁇ and the porosity was adjusted to about 90%.
  • Bone marrow cells were collected from the femur of a 7-week-old male male rat.
  • the collected bone marrow cells were cultured in Minimum Essential Medium (MEM medium) supplemented with 15% fetal calf serum and antibiotics (penicillin 1000 U / ml, streptomycin 0.1 mg / ml, amphotericin B 0.25 ⁇ ig / ml).
  • MEM medium Minimum Essential Medium
  • antibiotics penicillin 1000 U / ml, streptomycin 0.1 mg / ml, amphotericin B 0.25 ⁇ ig / ml.
  • Primary culture was performed for one day. Culturing was carried out at 37 ° C, 5% C0 2 below. Thereafter, a cell suspension was prepared by trypsin-EDTA treatment, and the cell concentration was adjusted to 10 6 cells / ml.
  • a cell / ⁇ -TCP complex was prepared by immersing the ⁇ -TCP block in the above cell suspension.
  • Cells /) 3 -TCP complex the medium 10 ⁇ 8 ⁇
  • Dexamethasone Sigma Chemical Co., St Louis, USA Seo, lOmM ⁇ -glycerophosphate (Sigma Chemical Co. , St Louis, US)> 50 ⁇ g / ml VitaminC phosphate (L-ascoroic acid phosphate magnesium salt n _ hydrate> Sigma Chemical Co., St Louis, USA) were added thereto to carry out a 20-day subculture. in the culture, media exchange was performed three times a week, the In each case, 3) -glycerophosphate Dexamethasone and OitaminC phosphate were added to the culture solution.
  • Solution A consisting of a suspension of fibrinogen (80 mg) and fibrin stabilizing factor XIII (75 units) in 1 ml of plasmin inhibitor and aprotinin (1000 kIE / ml) (Kumamoto, Japan).
  • Example 12 Bone formation using a composition for transplantation (fibrinogen-1) 3-TCP-cell-containing composition
  • the bone regeneration ability was evaluated by histological observation of the transplanted part at 2, 4 and 8 weeks after transplantation.
  • the transplanted part was removed, fixed with 10% phosphate buffer formalin, and then decalcified with 10% formic acid aqueous solution. Thereafter, tissue staining sections were prepared by embedding in paraffin, stained with hematoxylin and eosin (H.E.), and observed under an optical microscope.
  • FIG. 15 is a photograph showing a directly observed transplantation site 8 weeks after transplantation. A white lump is observed at the transplant (arrow).
  • Fig. 16 shows the H.E.-stained tissue images at 2 weeks (2W), 4 weeks (4W), and 8 weeks (8W) after transplantation of the transplanted part.
  • Two weeks after transplantation osteoblast lining is seen (arrow), indicating that bone formation is taking place.
  • bone cells became visible (arrows), indicating that active bone formation was progressing.
  • Eight weeks after transplantation some lamellar structures are seen (arrows), and bone maturation can be observed.
  • FIG. 17 is a HE-stained tissue image of the control group at 8 weeks after transplantation.
  • Figure 1 As shown in Fig. 7, the control group showed only a slight bone formation 8 weeks after transplantation.
  • PRP was isolated and purified from rat peripheral blood in the same manner as in Example 1. From each blood sample (50 ml), about 5 m of PRP was finally obtained.
  • the iliac bone marrow fluid was collected from a human iliac bone using a bone marrow puncture needle into a lOcc syringe (manufactured by Terumo Corporation) and injected into a centrifugal tube containing a heparin-containing basic medium.
  • the flask inoculated with the bone marrow fluid was transferred into Incube overnight, and cultured under the conditions of 5% C02, 37.
  • the medium was replaced 24 hours after seeding the bone marrow cells in order to remove the blood cells contained in the culture medium and select and adherent cells for culture. Thereafter, culturing was continued for about 7 days in the culture solution until the cells became subconfluent. During that time, medium exchange was performed once every three days.
  • the flask seeded with bone marrow fluid was transferred into the Inkyubeta, under conditions of 5% C0 2, 37 ° C Cultured.
  • the medium was replaced 24 hours after seeding the bone marrow cells in order to remove the blood cells contained in the culture medium and select and adherent cells for culture. After that, the culture was continued for about 7 days in the culture solution until it became subconfluent. During that time, the medium was changed once every three days.
  • MSCGM, 50 U / ml penicillin G, and 50 g / ml streptomycin manufactured by Poietics
  • the medium was removed from the flask, leaving a small amount of medium.
  • the cells were detached from the flask using Trypsin / EDTA.
  • the detached cells were transferred to a centrifuge tube (FALCON ECTON DICKINSON USA) together with the medium, and subjected to a centrifugation treatment (1500 rpm, 5 min). The supernatant was aspirated and the cell components were collected.
  • Example 15 Preparation of transplantation composition (PRP-alginate-cell-containing composition)
  • the cell component recovered in Example 14 was suspended in a small amount of PRP to prepare a cell suspension.
  • About 0.15 ml of the obtained PRP was mixed in a syringe to form a composition for transplantation (PRP-arginine-cell-containing composition).
  • Example 16 Bone formation using a composition for transplantation (PRP-alginate-cell-containing composition)
  • composition for transplantation About 1.5 ml of the composition for transplantation was subcutaneously transplanted to the back of a 4-week-old KSN nude mouse. On the other hand, those to which an arginite was transplanted in place of the composition for transplantation were used as a control group.
  • FIG. 18 shows an H.E.-stained tissue image of 16 weeks after transplantation ((A) is a group transplanted with the composition for transplantation, (B) is a control group). In the group (A) into which the transplant composition was transplanted, new bone was observed (arrow), and it was confirmed that bone regeneration was performed.
  • the composition for forming bone or periodontal tissue of the present invention can repair and regenerate bone tissue or periodontal tissue. It can be applied to various fields required. For example, it can be applied to bone augmentation when implanting artificial dental roots in a ridge with high bone resorption. In addition, the present invention can be applied to regeneration of bone tissue at a bone defect caused by trauma or various bone diseases, and reinforcement or supplementation of bone. In addition, the present invention can be applied to regeneration of alveolar bone and periodontal tissue in a defective portion of alveolar bone due to periodontal disease or the like. As an application method, a bone-forming composition such as a gel or a paste is filled, injected, or applied to the application site.
  • a bone-forming composition such as a gel or a paste is filled, injected, or applied to the application site.
  • the composition for synthesizing bone or periodontal tissue of the present invention contains a large number of growth factors capable of promoting the proliferation or differentiation of cells of the osteogenic system. Therefore, the cells of the osteogenic system can be efficiently proliferated or differentiated at the application part (transplantation part), and the formation of bone tissue or periodontal tissue can be promoted.
  • the use of autologous PRP is considered to improve the quality and quantity of bone tissue or periodontal tissue regeneration by the above non-toxic and immunoinactive growth factors.
  • the first aspect of the present invention contains an inorganic bioabsorbable material serving as a scaffold for bone-forming cells, the growth of the bone-forming cells in the application portion is promoted, and appropriate plasticity is imparted. The form can be maintained.
  • the composition for forming bone or periodontal tissue of the present invention since it has a gel-like fluidity, it can be easily inserted into the application area using a syringe needle or the like (it is also possible to apply without opening the wound area). High versatility without the need for pre-molding. As described above, by using the composition for forming bone or periodontal tissue of the present invention, it is not necessary to collect autologous bone and subject it to transplantation, and it is possible to easily grow bone or periodontal tissue. Become.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des compositions stimulant la formation d'un os ou d'un parodonte et présentant d'excellentes propriétés de manipulation ainsi qu'une grande innocuité. Selon cette invention, un os défectueux ou un parodonte peut être réparé de manière efficace et régénéré sans prélèvement d'os autologue. A cet effet, on prépare une composition sous forme de gel, en mélangeant du plasma riche en plaquettes (PRP) avec du ?-TCP ayant une taille de grain moyenne comprise entre 1 et 5 ?m puis en agitant le mélange obtenu avec de la thrombine et une solution de chlorure de calcium.
PCT/JP2001/009800 2000-11-14 2001-11-08 Compositions stimulant la formation d'un os ou d'un parodonte et injections pour la formation d'un os ou d'un parodonte Ceased WO2002040071A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002212739A AU2002212739A1 (en) 2000-11-14 2001-11-08 Compositions for forming bone or periodontium and injections for forming bone orperiodontium
JP2002542441A JPWO2002040071A1 (ja) 2000-11-14 2001-11-08 骨又は歯周組織形成用組成物、及び骨又は歯周組織形成用注射剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2000347287 2000-11-14
JP2000-347287 2000-11-14
JP2001-36415 2001-02-14
JP2001036415 2001-02-14
JP2001-150010 2001-05-18
JP2001150010 2001-05-18

Publications (1)

Publication Number Publication Date
WO2002040071A1 true WO2002040071A1 (fr) 2002-05-23

Family

ID=27345189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/009800 Ceased WO2002040071A1 (fr) 2000-11-14 2001-11-08 Compositions stimulant la formation d'un os ou d'un parodonte et injections pour la formation d'un os ou d'un parodonte

Country Status (3)

Country Link
JP (1) JPWO2002040071A1 (fr)
AU (1) AU2002212739A1 (fr)
WO (1) WO2002040071A1 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012750A1 (fr) * 2002-08-02 2004-02-12 Emi Sumida Procede de preparation de plasma riche en plaquettes
JP2004143067A (ja) * 2002-10-23 2004-05-20 Kazutomo Inoue 血管新生誘導剤
JP2004305260A (ja) * 2003-04-02 2004-11-04 Olympus Corp 生体組織補填体とその製造方法
JP2005111130A (ja) * 2003-10-10 2005-04-28 Olympus Corp 骨補填材の製造方法
JP2005110710A (ja) * 2003-10-02 2005-04-28 Olympus Corp 骨補填材及びその製造方法
JP2005170816A (ja) * 2003-12-09 2005-06-30 Naoki Ishiguro 軟骨修復用材料、およびその製造方法
WO2006123579A1 (fr) * 2005-05-17 2006-11-23 National University Corporation Nagoya University Procede de preparation cellulaire pour la formation de tissu osseux et application de cellule pour la formation de tissu osseux
JP2006346420A (ja) * 2005-06-13 2006-12-28 Univ Nagoya 移植材料及び骨質改善剤
JP2007037635A (ja) * 2005-08-01 2007-02-15 Hitachi Medical Corp 歯周組織再生用ゲル化組成物
US7497686B2 (en) 2004-09-02 2009-03-03 Odontis Ltd. Bone regeneration
WO2011048803A1 (fr) * 2009-10-20 2011-04-28 日東電工株式会社 Matériau pour induction de la régénération de tissus durs
JP2011525380A (ja) * 2008-06-23 2011-09-22 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク リン酸カルシウムを含有する生体材料
WO2014017147A1 (fr) 2012-07-27 2014-01-30 株式会社ジーシー Construction pour régénération de tissus et son procédé de production
JP2014057595A (ja) * 2005-12-13 2014-04-03 President & Fellows Of Harvard College 細胞移植のための足場
JP2016052520A (ja) * 2006-07-21 2016-04-14 ゲネラ・イストラジヴァンジャ・ディーオーオー 骨および軟組織欠損および障害の診断および処置のためのｂｍｐ−１プロコラーゲンｃ−プロテイナーゼ
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US9381235B2 (en) 2009-07-31 2016-07-05 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
EP3144017A1 (fr) * 2015-09-17 2017-03-22 Metrex Research LLC Matériau de remplissage à base de hydroxyapatite enrichi au plasma et son procédé de formation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9821045B2 (en) 2008-02-13 2017-11-21 President And Fellows Of Harvard College Controlled delivery of TLR3 agonists in structural polymeric devices
US9937249B2 (en) 2012-04-16 2018-04-10 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US12258430B2 (en) 2018-09-19 2025-03-25 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12274744B2 (en) 2016-08-02 2025-04-15 President And Fellows Of Harvard College Biomaterials for modulating immune responses
US12514865B2 (en) 2019-09-23 2026-01-06 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0345267A (ja) * 1989-07-12 1991-02-26 Mitsubishi Materials Corp 骨欠損部及び骨空隙部充てん材
WO1993016657A1 (fr) * 1992-02-28 1993-09-02 Collagen Corporation Compositions ceramiques injectables et leur procede de preparation et d'utilisation
WO1994007548A1 (fr) * 1992-09-30 1994-04-14 Inoteb Procede de preparation d'une colle biologique enrichie en facteurs plaquettaires et application
JPH10243996A (ja) * 1997-03-07 1998-09-14 Kagaku Gijutsu Shinko Jigyodan 硬組織石灰化促進用生体材料
JPH11253547A (ja) * 1998-03-11 1999-09-21 Kunio Ishikawa 細胞遮断膜

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0345267A (ja) * 1989-07-12 1991-02-26 Mitsubishi Materials Corp 骨欠損部及び骨空隙部充てん材
WO1993016657A1 (fr) * 1992-02-28 1993-09-02 Collagen Corporation Compositions ceramiques injectables et leur procede de preparation et d'utilisation
WO1994007548A1 (fr) * 1992-09-30 1994-04-14 Inoteb Procede de preparation d'une colle biologique enrichie en facteurs plaquettaires et application
JPH10243996A (ja) * 1997-03-07 1998-09-14 Kagaku Gijutsu Shinko Jigyodan 硬組織石灰化促進用生体材料
JPH11253547A (ja) * 1998-03-11 1999-09-21 Kunio Ishikawa 細胞遮断膜

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARX R.E. ET AL.: "Platelet rich plasma: growth factor enhancement for bone grafts", ORAL SURGERY, MEDICINE, PATHOLOGY, RADIOLOGY AND ENDODONTICS, vol. 85, no. 6, 1998, pages 638 - 646, XP002909077 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012750A1 (fr) * 2002-08-02 2004-02-12 Emi Sumida Procede de preparation de plasma riche en plaquettes
JP2004143067A (ja) * 2002-10-23 2004-05-20 Kazutomo Inoue 血管新生誘導剤
JP2004305260A (ja) * 2003-04-02 2004-11-04 Olympus Corp 生体組織補填体とその製造方法
JP2005110710A (ja) * 2003-10-02 2005-04-28 Olympus Corp 骨補填材及びその製造方法
JP2005111130A (ja) * 2003-10-10 2005-04-28 Olympus Corp 骨補填材の製造方法
JP2005170816A (ja) * 2003-12-09 2005-06-30 Naoki Ishiguro 軟骨修復用材料、およびその製造方法
US7497686B2 (en) 2004-09-02 2009-03-03 Odontis Ltd. Bone regeneration
WO2006123579A1 (fr) * 2005-05-17 2006-11-23 National University Corporation Nagoya University Procede de preparation cellulaire pour la formation de tissu osseux et application de cellule pour la formation de tissu osseux
JPWO2006123579A1 (ja) * 2005-05-17 2008-12-25 国立大学法人名古屋大学 骨組織形成用細胞の調製方法、及び骨組織形成用細胞の利用
JP2006346420A (ja) * 2005-06-13 2006-12-28 Univ Nagoya 移植材料及び骨質改善剤
JP2007037635A (ja) * 2005-08-01 2007-02-15 Hitachi Medical Corp 歯周組織再生用ゲル化組成物
US10149897B2 (en) 2005-12-13 2018-12-11 President And Fellows Of Harvard College Scaffolds for cell transplantation
US9446107B2 (en) 2005-12-13 2016-09-20 President And Fellows Of Harvard College Scaffolds for cell transplantation
US10137184B2 (en) 2005-12-13 2018-11-27 President And Fellows Of Harvard College Scaffolds for cell transplantation
JP2014057595A (ja) * 2005-12-13 2014-04-03 President & Fellows Of Harvard College 細胞移植のための足場
US11096997B2 (en) 2005-12-13 2021-08-24 President And Fellows Of Harvard College Scaffolds for cell transplantation
JP2015226540A (ja) * 2005-12-13 2015-12-17 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞移植のための足場
JP2017079778A (ja) * 2005-12-13 2017-05-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞移植のための足場
JP2016052520A (ja) * 2006-07-21 2016-04-14 ゲネラ・イストラジヴァンジャ・ディーオーオー 骨および軟組織欠損および障害の診断および処置のためのｂｍｐ−１プロコラーゲンｃ−プロテイナーゼ
US10258677B2 (en) 2008-02-13 2019-04-16 President And Fellows Of Harvard College Continuous cell programming devices
US9821045B2 (en) 2008-02-13 2017-11-21 President And Fellows Of Harvard College Controlled delivery of TLR3 agonists in structural polymeric devices
US10568949B2 (en) 2008-02-13 2020-02-25 President And Fellows Of Harvard College Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9233124B2 (en) 2008-06-23 2016-01-12 Centre National De La Recherche Scientifique Biomaterials containing calcium phosphate
US9421227B2 (en) 2008-06-23 2016-08-23 Centre National De La Recherche Scientifique Biomaterials containing calcium phosphate
JP2011525380A (ja) * 2008-06-23 2011-09-22 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク リン酸カルシウムを含有する生体材料
JP2014195712A (ja) * 2008-06-23 2014-10-16 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク リン酸カルシウムを含有する生体材料
US9381235B2 (en) 2009-07-31 2016-07-05 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US10080789B2 (en) 2009-07-31 2018-09-25 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US9040070B2 (en) 2009-10-20 2015-05-26 Nitto Denko Corporation Material for induction of hard tissue regeneration
JPWO2011048803A1 (ja) * 2009-10-20 2013-03-07 日東電工株式会社 硬組織再生誘導用材料
CN102665775A (zh) * 2009-10-20 2012-09-12 日东电工株式会社 诱导硬组织再生的材料
WO2011048803A1 (fr) * 2009-10-20 2011-04-28 日東電工株式会社 Matériau pour induction de la régénération de tissus durs
US11202759B2 (en) 2010-10-06 2021-12-21 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US12427118B2 (en) 2011-04-28 2025-09-30 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US10406216B2 (en) 2011-06-03 2019-09-10 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US9937249B2 (en) 2012-04-16 2018-04-10 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
US11278604B2 (en) 2012-04-16 2022-03-22 President And Fellows Of Harvard College Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses
WO2014017147A1 (fr) 2012-07-27 2014-01-30 株式会社ジーシー Construction pour régénération de tissus et son procédé de production
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US11998593B2 (en) 2014-04-30 2024-06-04 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
EP3144017A1 (fr) * 2015-09-17 2017-03-22 Metrex Research LLC Matériau de remplissage à base de hydroxyapatite enrichi au plasma et son procédé de formation
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US12274744B2 (en) 2016-08-02 2025-04-15 President And Fellows Of Harvard College Biomaterials for modulating immune responses
US12258430B2 (en) 2018-09-19 2025-03-25 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12514865B2 (en) 2019-09-23 2026-01-06 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof

Also Published As

Publication number Publication date
JPWO2002040071A1 (ja) 2004-03-18
AU2002212739A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
WO2002040071A1 (fr) Compositions stimulant la formation d'un os ou d'un parodonte et injections pour la formation d'un os ou d'un parodonte
JP5408578B2 (ja) 歯髄幹細胞を用いた自家又は同種移植用組成物及びその用途
JP4982841B2 (ja) 再生医療骨組成物
Qiu et al. Bone regeneration in minipigs via calcium phosphate cement scaffold delivering autologous bone marrow mesenchymal stem cells and platelet‐rich plasma
Sun et al. Emerging roles of platelet concentrates and platelet-derived extracellular vesicles in regenerative periodontology and implant dentistry
JP2011516436A (ja) 幹細胞又は骨髄細胞を用いる組織の再生のための方法及び組成物
Zhu et al. A comparative histologic analysis of tissue-engineered bone using platelet-rich plasma and platelet-enriched fibrin glue
Alshehadat et al. Scaffolds for dental pulp tissue regeneration: A review
JP2012515041A (ja) 骨粉末とフィブリングルーからなる固形のスキャフォールド
US20090298173A1 (en) Method of preparing cell for bone tissue formation and application of cell for bone tissue formation
CN112587729A (zh) 一种骨修复材料
JP5456031B2 (ja) 血液と二相性リン酸カルシウムセラミック粒子との組合せ
CN102123744A (zh) 包含磷酸钙的生物材料
JP2006122518A (ja) 骨又は歯周組織形成用組成物
JP2014230685A (ja) 歯周組織形成用材料
WO2002017983A1 (fr) Compositions medicinales pour la formation de tissu autour d'un os ou d'une dent, procede de preparation desdites compositions, substances a injecter pour la formation de tissu autour d'un os ou d'une dent et procede de preparation desdites substances
Rady Comparing the osteogenic and bone regenerative capacities of MTA, nano MTA, nano hydroxyapatite and injectable platelet rich fibrin in a rat bony defect model. An in vivo study
JP4842579B2 (ja) 歯周組織再生用ゲル化組成物
RU2809154C1 (ru) Тканебиоинженерная конструкция для восполнения объема костной ткани челюстных костей
Eissa et al. Effect of autogenous bone marrow mesenchymal stem cells in healing of mandibular osseous defects grafted with beta tricalcium phosphate in dogs
Tuersun et al. Application of filling materials in autologous tooth transplantation
Abdelhamid et al. Implications of Platelet-Rich Fibrin in Oral and Maxillofacial Surgery: A Review
JP3820396B2 (ja) 微細骨粉を含浸させた生体適合性材料からなる構造体およびその製造方法
de Mello et al. Major considerations of the biological mechanisms of bone regeneration through mesenchymal stem cells, exosomes, and microRNAs in the scenario of bucco-maxillo-facial surgery: a systematic review
Fattah et al. Nanotechnology in tooth-tissue regenerative therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002542441

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase